Regulatory Accord, Intas, and Bio-Thera File Four IPRs Against Janssen Golimumab Patents Big Molecule WatchOn March 20, 2026, Accord BioPharma, Inc.RegulatoryImmunology & InflammationRead full story pharminent March 27, 2026 (Last updated: March 30, 2026) Big Molecule Watch On March 20, 2026, Accord BioPharma, Inc. RegulatoryImmunology & InflammationRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Otsuka picks up PTSD drug with $700M Transcend buyNext: S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
